𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A multicenter randomized controlled trial of recombinant interferon-α2b in patients with acute transfusion-associated hepatitis C

✍ Scribed by Pietro Lampertico; Mariagrazia Rumi; Raffaella Romeo; Antonio Craxi; Roberta Soffredini; Daniela Biassoni; Massimo Colombo

Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
462 KB
Volume
19
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Recombinant human α-interferon in patien
Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France
✍ Patrick Marcellin; Nathalie Boyer; Emile Giostra; Claude Degott; Anne Marie Cour 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 466 KB

We have conducted a multicenter randomized controlled trial comparing two doses of recombinant human a-interferon for efficacy in 60 patients with chronic non-A, non-B hepatitis. The source of infection appeared to be transfusion in 30 patients, intravenous drug abuse in 16 patients and was unknown

Treatment of chronic hepatitis C with co
Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial
✍ M J Tong; K R Reddy; W M Lee; P J Pockros; J C Hoefs; E B Keeffe; F B Hollinger; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 222 KB 👁 1 views

AND THE CONSENSUS INTERFERON STUDY GROUP 15 tion. Efficacy was assessed by normalization of serum alanine This multicenter, randomized, controlled, double-blind, transaminase (ALT) concentration and decrease in serum hepphase III study in 704 patients with chronic hepatitis C infecatitis C virus (HC

Response to higher doses of interferon a
Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial
✍ K L Lindsay; G L Davis; E R Schiff; H C Bodenheimer; L A Balart; J L Dienstag; R 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 1 views

JANICE ALBRECHT, 12 AND THE HEPATITIS INTERVENTIONAL THERAPY GROUP\* with continued therapy at that dose; however, a propor-To evaluate response rates to 3, 5, or 10 million units tion of patients who do not respond to 12 weeks of treat-(MU) of interferon alfa-2b, given thrice weekly, and to ment wi

A randomised controlled trial of recombi
A randomised controlled trial of recombinant interferon-γ in chinese patients with chronic hepatitis B virus infection
✍ Johnson Y. N. Lau; Dr. C. L. Lai; P. C. Wu; H. T. Chung; Anna S. F. Lok; H. J. L 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 433 KB

## Abstract Nineteen Chinese patients with chronic hepatitis B virus (HBV) infection, seropositive for HBV e antigen (HBeAg) and HBV DNA on at least three occasions in 6 months, were randomised to receive either recombinant human interferongamma (rlFNγ) 0.1 mg/m^2^ intramuscularly thrice weekly for

Efficacy of thymosin α1 in patients with
Efficacy of thymosin α1 in patients with chronic hepatitis B: A randomized, controlled trial
✍ Rong-Nan Chien; Yun-Fan Liaw; Tse-Ching Chen; Chau-Ting Yeh; I.-Shyan Sheen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 1 views

Thymosin ␣ 1 (T␣) is an immune modifier that has been shown in a pilot study to be effective for chronic hepatitis B; this requires confirmation. Ninety-eight patients with clinicopathologically proven chronic hepatitis B were randomly allocated to 3 groups: 1) group A received a 26-week course of T

Better efficacy of a 12-month interferon
Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: A multicenter, controlled, randomized trial
✍ Jean-Louis Payen; Jacques Izopet; Virginie Galindo-Migeot; Valérie Lauwers-Cance 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 320 KB 👁 1 views

We studied the efficacy of three interferon alfa-2b (IFN-2b) regimens for the retreatment of patients with chronic hepatitis C (CHC) with prior complete response followed by relapse. Consecutive patients with CHC who had a complete biochemical response but relapse after a first course of 6 months of